Two single‐arm, phase II studies (NCT02954536, NCT02901301) have demonstrated the clinical efficacy and safety for the combination of anti‐PD1 antibody, trastuzumab, and chemotherapy in metastatic HER2‐positive GC patients.10, 11, 12. The gene discussed is ERBB2; the disease is gastric cancer.